Consentement d'utilisation des Cookies

J'accepte Notre site sauvegarde des traceurs textes (cookies) sur votre appareil afin de vous garantir de meilleurs contenus et à des fins de collectes statistiques.Vous pouvez désactiver l'usage des cookies en changeant les paramètres de votre navigateur. En poursuivant votre navigation sur notre site sans changer vos paramètres de navigateur vous nous accordez la permission de conserver des informations sur votre appareil.

51481-61-9 - Cimetidine, 98+% - 1-Cyano-3-methyl-2-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine - SKF-92334 - J62825 - Alfa Aesar

J62825 Cimetidine, 98+%

Numéro CAS
51481-61-9
Synonymes
1-Cyano-3-methyl-2-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine
SKF-92334

Dimensions Prix ($) Quantité Disponibilité
5g 80,55
10g 101,00
25g 175,20
Ajouter au panier Ajouter au devis en vrac Afficher l'article

Cimetidine, 98+%

MDL
MFCD00133296
EINECS
257-232-2

Propriétés chimiques

Formule
C10H16N6S
Poids formulaire
252.34
Forme
Powder
Point de fusion
139-144°
Solubilité
Soluble to 50 mM in water and to 100 mM in DMSO, solubility in HCl (almost transparency).

Applications

Widely used H2 histamine antagonist which has more recently been described as an inverse agonist. Also a potent I1 imidazoline binding site ligand. It displays antitumor and immunomodulatory activity. Cimetidine competitively inhibits histamine binding to histamine H2 receptors, and suppresses the growth of several tumors, including gastrointestinal cancer. This compound is an anti-angiogenic agent and is an activator of Nischarin. Competitive histamine H2-receptor antagonist which inhibits gastric acid secretion and reduces pepsin output

Notes

Store away from heat and oxidizing agents. Keep the container tightly closed and place it in a cool, dry and well ventilated condition.

Références bibliographiques

Yasui-Furukori N, et al. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.Clinical pharmacology and therapeutics.,2005,77(1), 17-23.

Yoshizawa F, et al. Time course of leucine-induced 4E-BP1 and S6K1 phosphorylation in the liver and skeletal muscle of rats.Journal of clinical pharmacology.,1981,21(2), 87-91.

Mentions de danger et de prudence du SGH

Mentions de danger (UE): H360-H303

May damage fertility or the unborn child. May be harmful if swallowed.

Mentions de prudence: P201-P281-P202-P312-P308+P313-P405-P501a

Obtain special instructions before use. Use personal protective equipment as required. Do not handle until all safety precautions have been read and understood. Call a POISON CENTER or doctor/physician if you feel unwell. IF exposed or concerned: Get medical advice/attention. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.

Autres références

Merck
14,2279
Code tarifaire harmonisé
2933.29
TSCA
No
RTECS
MF0035500

Recommandé

Consulté récemment

Produits chimiques

Sciences de la vie

Métaux et matériaux

Catalyseurs

Analytique et matériel de laboratoire